User:Mr. Ibrahem/Octreotide
From Wikipedia, the free encyclopedia
Octreotide, sold under the brand name Sandostatin among others, is a medication used to treat carcinoid syndrome, acromegaly, congenital hyperinsulinism, and gastrointestinal bleeding due to esophageal varices.[1][2] It can be given by injection into a vein or muscle.[1] The immediate release form may be effective up to 12 hours.[1]
Clinical data | |
---|---|
Trade names | Sandostatin, Bynfezia Pen, Mycapssa, others |
AHFS/Drugs.com | Monograph |
MedlinePlus | a693049 |
License data |
|
Pregnancy category |
|
Routes of administration | Subcutaneous, intramuscular, intravenous, by mouth |
Drug class | Somatostatin[1] |
Legal status | |
Legal status | |
Pharmacokinetic data | |
Bioavailability | 60% (IM), 100% (SC) |
Protein binding | 40–65% |
Metabolism | Liver |
Elimination half-life | 1.7–1.9 hours |
Excretion | Urine (32%) |
Identifiers | |
| |
Chemical and physical data | |
Formula | C49H66N10O10S2 |
Molar mass | 1019.25 g·mol−1 |
3D model (JSmol) | |
| |
| |
NY (what is this?) (verify) |
Common side effects include nausea, a slow heart rate, and abdominal discomfort.[1] Other side effects may include low or high blood sugar, gall bladder problems, and anaphylaxis.[1] It is unclear if use during pregnancy is safe.[3] Use is not recommended when breastfeeding.[4] It mimics the effects of natural somatostatin and inhibits the release of growth hormone, serotonin, insulin, and glucagon.[1]
It was first made in 1979, by the chemist Wilfried Bauer.[5] It was approved for medical use in the United States in 1988.[6] It is available as a generic medication.[4] In the United Kingdom it costs about 3 pounds per 50 ug dose as of 2020.[4] In the United States this amount costs about 5.30 USD as of 2020.[7]